Slingshot Therapeutics

Slingshot, the Syncona Accelerator, is focused on accumulating a pipeline of early-stage programmes, identified from world-leading academic institutions, and accelerating their development towards the clinic.

Slingshot benefits from Syncona’s expertise in creating and building companies from early-stage science. Through a high-quality management team, Slingshot offers academic founders access to development expertise that is rarely available to singular early-stage programmes, as well as centralised resource, funding and operational support. This enables Slingshot to rapidly advance its programmes and create a variety of options to further progress them through the clinic and ultimately to patients.

Slingshot is led by Managing Partner Edward Hodgkin, as Executive Chair of the company.